PALB2 and familial pancreatic carcinoma: Additionally, in a Phase II study investigating the efficacy of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer harboring pathogenic germline or somatic variants, two PR and one complete response (CR) were observed in six patients with germline PALB2 pathogenic variants (gPALB2m) following rucaparib treatment (Reiss et al., 2021).